Pharma commercial intelligence, news & analysis

Evaluate radically transforms your confidence in strategic portfolio decisions.

When you partner with Evaluate, our constantly expanding solutions and transparent methodologies and datasets are instantly at your disposal, along with expert, personalised support.

Evaluate provides a complete and dynamic valuation of pharma assets, turning understanding into insight, and insight into action.

HOW WE CAN HELP YOU

Market Reports

Thought Leadership

Read our wide range of complimentary market reports covering sector performance and valuation, market trends and global forecasts, including our annual Evaluate Pharma World Preview.

READ OUR REPORTS

OUR PRODUCTS

Evaluate Pharma

Get a global view of the pharmaceutical market’s past, present and future performance with over two decades of commercial data and consensus forecasts to 2026.

FIND OUT MORE

OUR SERVICES

Pharma Consulting & Analytics

Improve your strategic decision-making with customised, data-driven solutions that draw on our collaborative team of industry experts and trusted commercial intelligence.

FIND OUT MORE

February 01, 2023

Novartis trims its pipeline

Discontinuations for branaplam, iptacopan and Piqray could increase pipeline scepticism, but more pruning is coming.

January 31, 2023

Astrazeneca gets personal

A collaboration this week with the blood testing specialist Capitainer underlines the big pharma’s ambition to have a diagnostic linked with every pipeline project.

January 30, 2023

Go or no go? Overcoming delays

January 30, 2023

The end of the Humira era

January 27, 2023

Pharma commercial intelligence, news & analysis | Evaluate

Evaluate radically transforms your confidence in strategic portfolio decisions.

Novartis trims its pipeline

Astrazeneca gets personal

Go or no go? Overcoming delays

The end of the Humira era

Anthos doubles down on its novel blood thinner